{"entity":{"id":"nct06618287","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Osimertinib, Pembrolizumab, Nivolumab and PM8002 in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.","summary":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06618287 by Bristol-Myers Squibb, with 416 participants planned, started 2025-02-04 and due to reach its primary completion in 2031-02-26. Interventions recorded: BMS-986507, Osimertinib, Pembrolizumab, Nivolumab and Pumitamig.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06618287","url":"https://clinicaltrials.gov/study/NCT06618287"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["osimertinib","pembrolizumab","nivolumab","pm8002"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06618287","phase":"1/2","setting":"A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors","sponsor":"Bristol-Myers Squibb","participation":[{"nct":"NCT06618287","source":"https://clinicaltrials.gov/study/NCT06618287","fetchedAt":"2026-10-07T16:54:51.841Z","studySha256":"b2c3734b20e2cf87ba7945a45efb24a380c6cd968431e460b99770f5f9953cf5","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-23","leadSponsor":"Bristol-Myers Squibb","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":416,"enrolmentType":"ESTIMATED","siteCount":65,"recruitingSiteCount":47,"countries":["Australia","Canada","Chile","France","Italy","Netherlands","Spain","Taiwan","United Kingdom","United States"]}],"started":"2025-02-04","startedType":"actual","enrolled":416,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06618287/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}